X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, MSRD and Sentinel will collaborate to support the Phase 1a and Phase 1b clinical trials for Sentinel’s investigational compound SOL784 with the opportunity to expand the collaboration after those studies.
Lead Product(s): SOL784
Therapeutic Area: Genetic Disease Product Name: SOL784
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: McQuade Center for Strategic Research and Development
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 03, 2021
Details:
Under the terms of the Agreement, Sentinel Oncology will receive an exclusivity payment and PharmaEngine will obtain an option to receive the exclusive rights to develop and commercialize SOL-578 worldwide.
Lead Product(s): SOL-578
Therapeutic Area: Oncology Product Name: SOL-578
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaEngine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
